Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors

Por Chiu, Yi-Lin, LoRusso, Patricia, Hosmane, Balakrishna, Ricker, Justin L., Awni, Walid, Carlson, Dawn M.
Publicado em 2013

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

Por Badri, Prajakta S., Dutta, Sandeep, Wang, Haoyu, Podsadecki, Thomas J., Polepally, Akshanth R., Khatri, Amit, Zha, Jiuhong, Chiu, Yi-Lin, Awni, Walid M., Menon, Rajeev M.
Publicado no Antimicrob Agents Chemother (2015)

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers...

Por Polepally, Akshanth R., King, Jennifer R., Ding, Bifeng, Shuster, Diana L., Dumas, Emily O., Khatri, Amit, Chiu, Yi-Lin, Podsadecki, Thomas J., Menon, Rajeev M.
Publicado no Clin Pharmacokinet (2016)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

Por Asahina, Hajime, Tamura, Yosuke, Nokihara, Hiroshi, Yamamoto, Noboru, Seki, Yoshitaka, Shibata, Takashi, Goto, Yasushi, Tanioka, Maki, Yamada, Yasuhide, Coates, Andrew, Chiu, Yi-Lin, Li, Xiaohui, Pradhan, Rajendra, Ansell, Peter J., McKeegan, Evelyn M., McKee, Mark D., Carlson, Dawn M., Tamura, Tomohide
Publicado em 2012

Natural Endogenous Human Matriptase and Prostasin Undergo Zymogen Activation via Independent Mechanisms in an Uncoupled Manner

Por Su, Hui Chen, Liang, Yan A., Lai, Ying-Jung J., Chiu, Yi-Lin, Barndt, Robert B., Shiao, Frank, Chang, Hsiang-Hua D., Lu, Dajun D., Huang, Nanxi, Tseng, Chun-Che, Wang, Jehng-Kang, Lee, Ming-Shyue, Johnson, Michael D., Huang, Shih-Ming, Lin, Chen-Yong
Publicado no PLoS One (2016)

Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies

Por Wilson, Wyndham H., O’Connor, Owen A., Czuczman, Myron S., LaCasce, Ann S., Gerecitano, John F., Leonard, John P., Tulpule, Anil, Dunleavy, Kieron, Xiong, Hao, Chiu, Yi-Lin, Cui, Yue, Busman, Todd, Elmore, Steven W., Rosenberg, Saul H., Krivoshik, Andrew P., Enschede, Sari H., Humerickhouse, Rod A.
Publicado em 2010

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751

Por Innocenti, Federico, Ramírez, Jacqueline, Obel, Jennifer, Xiong, Julia, Mirkov, Snezana, Chiu, Yi-Lin, Katz, David A., Carr, Robert A., Zhang, Wei, Das, Soma, Adjei, Araba, Moyer, Ann M., Chen, Pei Xian, Krivoshik, Andrew, Medina, Diane, Gordon, Gary B., Ratain, Mark J., Sahelijo, Leonardo, Weinshilboum, Richard M., Fleming, Gini F., Bhathena, Anahita
Publicado em 2013

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Por Gandhi, Leena, Camidge, D. Ross, Ribeiro de Oliveira, Moacyr, Bonomi, Philip, Gandara, David, Khaira, Divis, Hann, Christine L., McKeegan, Evelyn M., Litvinovich, Elizabeth, Hemken, Philip M., Dive, Caroline, Enschede, Sari H., Nolan, Cathy, Chiu, Yi-Lin, Busman, Todd, Xiong, Hao, Krivoshik, Andrew P., Humerickhouse, Rod, Shapiro, Geoffrey I., Rudin, Charles M.
Publicado no J Clin Oncol (2011)